首页 | 本学科首页   官方微博 | 高级检索  
     

运用CRISPR/Cas9技术构建表达10rolGLP-1的降糖酵母
引用本文:张金睿,杨佳明,孟钰杰,邢曙光,刘奇奇,李明刚. 运用CRISPR/Cas9技术构建表达10rolGLP-1的降糖酵母[J]. 生物工程学报, 2023, 39(9): 3747-3756
作者姓名:张金睿  杨佳明  孟钰杰  邢曙光  刘奇奇  李明刚
作者单位:南开大学生命科学学院 生物活性材料教育部重点实验室 药物化学生物学国家重点实验室, 天津 300071
基金项目:国家自然科学基金(31771066);天津市重点技术研发计划(18YFZCSY00030,18YFZCNC01200)
摘    要:为研发一种用于治疗2型糖尿病的新型生物药物,本研究运用实验室前期构建的10rolglp-1基因和CRISPR/Cas9基因组编辑技术创建了重组酿酒酵母(Saccharomyces cerevisiae)工程菌株。构建了向导RNA(guide RNA,gRNA)表达载体pyES2-gRNA、供体载体pNK1-L-PGK-10rolGLP-1-R和Cas9表达载体pGADT7-Cas9,将这些表达载体共转化酿酒酵母INVSc1菌株,通过同源重组途径敲入PGK-10rolGLP-1表达单元,最终得到具有降血糖功能、高表达10rolGLP-1的酿酒酵母。通过SDS-PAGE和蛋白质印迹,筛选出2种稳定表达10rolGLP-1的酿酒酵母重组菌株。降血糖实验结果表明,重组降血糖酿酒酵母对糖尿病小鼠模型具有显著的降血糖作用,其血糖下降平缓,可避免引起低血糖风险。体重变化和多尿等其他症状也明显改善,表明本研究构建的口服降血糖酿酒酵母有望成为一种简单有效、经济实用的糖尿病生物药物。

关 键 词:CRISPR/Cas9  胰高血糖素样肽-1(GLP-1)  酿酒酵母  2型糖尿病  生物药物
收稿时间:2022-11-02

Construction of a 10rolGLP-1-expressing glucose-lowing Saccharomyces cerevisiae by CRISPR/Cas9 technique
ZHANG Jinrui,YANG Jiaming,MENG Yujie,XING Shuguang,LIU Qiqi,LI Minggang. Construction of a 10rolGLP-1-expressing glucose-lowing Saccharomyces cerevisiae by CRISPR/Cas9 technique[J]. Chinese journal of biotechnology, 2023, 39(9): 3747-3756
Authors:ZHANG Jinrui  YANG Jiaming  MENG Yujie  XING Shuguang  LIU Qiqi  LI Minggang
Affiliation:State Key Laboratory of Medicinal Chemical Biology, Key Laboratory for Bioactive Materials of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin 300071, China
Abstract:To develop a novel glucose-lowering biomedicine with potential benefits in the treatment of type 2 diabetes, we used the 10rolGLP-1 gene previously constructed in our laboratory and the CRISPR/Cas9 genome editing technique to create an engineered Saccharomyces cerevisiae strain. The gRNA expression vector pYES2-gRNA, the donor vector pNK1-L-PGK-10rolGLP-1-R and the Cas9 expression vector pGADT7-Cas9 were constructed and co-transformed into S. cerevisiae INVSc1 strain, with the PGK-10rolGLP-1 expressing unit specifically knocked in through homologous recombination. Finally, an S. cerevisiae strain highly expressing the 10rolGLP-1 with glucose-lowering activity was obtained. SDS-PAGE and Western blotting results confirmed that two recombinant strains of S. cerevisiae stably expressed the 10rolGLP-1 and exhibited the desired glucose-lowering property when orally administered to mice. Hypoglycemic experiment results showed that the recombinant hypoglycemic S. cerevisiae strain offered a highly hypoglycemic effect on the diabetic mouse model, and the blood glucose decline was adagio, which can avoid the dangerous consequences caused by rapid decline in blood glucose. Moreover, the body weight and other symptoms such as polyuria also improved significantly, indicating that the orally hypoglycemic S. cerevisiae strain that we constructed may develop into an effective, safe, economic, practical and ideal functional food for type 2 diabetes mellitus treatment.
Keywords:CRISPR/Cas9  glucagon like peptide-1 (GLP-1)  Saccharomyces cerevisiae  type 2 diabetes mellitus  biomedicine
本文献已被 维普 等数据库收录!
点击此处可从《生物工程学报》浏览原始摘要信息
点击此处可从《生物工程学报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号